GGHC
PRVB

Gilder Gagnon Howe & Co’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-18,842
Closed -$199K – 266
2022
Q4 		$199K Buy
+18,842
New +$152K ﹤0.01% 238
2021
Q3 		– Sell
-288,070
Closed -$2.43M – 446
2021
Q2 		$2.43M Sell
288,070
-2,821,804
-91% -$22.8M 0.01% 297
2021
Q1 		$32.6M Buy
3,109,874
+750,192
+32% +$10.6M 0.18% 124
2020
Q4 		$40M Buy
2,359,682
+208,280
+10% +$3.12M 0.2% 117
2020
Q3 		$27.6M Buy
2,151,402
+900,142
+72% +$11.4M 0.17% 120
2020
Q2 		$17.7M Buy
+1,251,260
New +$15.8M 0.14% 123

Other funds holding PRVB

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Gilder Gagnon Howe & Co's PRVB Position: Q1 2023 in Review

Gilder Gagnon Howe & Co sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 18,842 shares — an estimated $199K sold.

Gilder Gagnon Howe & Co first reported a position in PRVB in Q2 2020 and held it in 6 quarters. The position peaked at $40M in Q4 2020. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

  • Gilder Gagnon Howe & Co reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 18,842 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $199K.
  • Gilder Gagnon Howe & Co first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
  • Gilder Gagnon Howe & Co's Provention Bio, Inc. Common Stock position peaked at $40M in Q4 2020.
  • 182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2023, filed 15 May 2023.